Chief Financial Officer · ImmunityBio, Inc. · Common Stock
Side
M
Value
—
Shares
82.2K
Price
—
Executed
Feb 10, 2026
Disclosed
Feb 12, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 10 executedFeb 12, 2026 disclosed
IBRX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+9 / 25
No reported dollar value · 34.2% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Sachs David C. filed this Form 4 reporting a option exercise of IBRX on Feb 10, 2026. It became public on Feb 12, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Sachs David C.cik:0001848899
Issuer
ImmunityBio, Inc.cik:0001326110
Revision history · 0
No field has changed since this record was first ingested.
